



HHCP-I Cryopreserved Plateable Human Hepatocytes for Induction Cell Specification		
Lot HH160512-2		Batch Release: July 01, 2016 Updated: Sept 27, 2019
Species: Human	Gender: female Size: 164 cm Non-smoker	Age: 73 years Weight: 85 kg
Serology: HAV, HBV, HCV, HIV 1/2: negative	Diagnosis: Metastasis of Sigmacarcinoma	
Medical History: Diabetes, Hypertension Medication: Enalapril, Bisoprolol, Omeprazol, Metformin, Dopegyt, Lercanidipin, Morphi Fentanyl	Therapy: Liver resection Segment S7/S8 w/o Chemotherapy	
Cryopreservation: Date: May 12, 2016 Amount per vial: 10.6 x 10 ⁶ cells	Thawing: n=2 Post-thaw viability: 78.2 ± 4.9 % Post-thaw yield per vial: 4.6 ± 0.9 x 10 ⁶ cells Recovery: 43 %	
Phase contrast on day 2 after thawing (24well plate)	Phase contrast on day 3 after thawing (24well plate)	
		
Recommended seeding density on collagen-coated plates: 24well plate – 540,000 cells/well Culture in Human Hepatocyte Maintenance Medium (HHMM).		
CYP P450 activity in culture after thawing: Ethoxyresorufin-O-deethylation: Induction with 10 µM beta-Naphthoflavone Induction with 25 µM beta-Naphthoflavone	pmol/(mg × min) 7.5 ± 3.8 52.7 ± 3.4	x-fold induction 2.8 19.7

Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.

Store at -150 °C or in the vapour phase of LN₂

This product should be considered as potential biohazard. Only intended for *in vitro* use.

Issued by: A. Ullrich
Updated by: A. Ullrich

Verified by: T. Krimmling
Verified by: C. Garve